Transgenic non-human animals for producing heterologous and chimeric antibodies

Abstract

The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.

Description

CROSS-REFERENCE TO RELATED APPLICATION [0001] This application is a continuation-in-part of U.S. Ser. No. 08 / 728,463 filed Oct. 10, 1996, which is a continuation-in-part of U.S. Ser. No. 08 / 544,404 filed 10 Oct. 1995, which is a continuation-in-part of U.S. Ser. No. 08 / 352,322 filed 7 Dec. 1994, which is a continuation-in-part of U.S. Ser. No. 08 / 209,741 filed Mar. 9, 1994, which is a continuation-in-part of U.S. Ser. No. 08 / 165,699 filed Dec. 10, 1993, which is a continuation-in-part os U.S. Ser. No. 08 / 161,739 filed Dec. 3, 1993, which is a continuation-in-part of U.S. Ser. No. 08 / 155,301 filed Nov. 18, 1993, which is a continuation-in-part of U.S. Ser. No. 08 / 096,762 filed Jul. 22, 1993, which is a continuation-in-part of U.S. Ser. No. 08 / 053,131 file d Apr. 26, 1993, which is a continuation-in-part of U.S. Ser. No. 07 / 990,860 filed Dec. 16, 1992, which is a continuation-in-part of U.S. Ser. No. 07 / 904,068 filed Jun. 23, 1992, which is a continuation-in-part of U.S. Ser. No. 07 / 8...

AI Technical Summary

Benefits of technology

[0028] This invention further provides methods that facilitate isotype switching of the transgene, so that switching between particular isotypes may occur at much higher or lower frequencies or in different temporal orders than typically occurs in germline immunoglobulin loci. Switch regions may be grafted from various CH genes and ligated to other CH genes in a transgene construct; such grafted switch sequences will typically function independently of the associated CH gene so that switching in the transgene construct will typically be a function of the origin of the associated switch regions. Alternatively, or in combination with switch sequences, δ-associated deletion sequences may be linked to various CH genes to effect non-classical switching by deletion of sequences between two δ-associated deletion sequences. Thus, a transgene may be constructed so that a particular CH gene is linked to a different switch sequence and thereby is switched to more frequently than occurs when the naturally associated switch region is used.

Problems solved by technology

For example, when immunocompetent human patients are administered therapeutic doses of rodent monoclonal antibodies, the patients produce antibodies against the rodent immunoglobulin sequences; these human anti-mouse antibodies (HAMA) neutralize the therapeutic antibodies and can cause acute toxicity.

However, producing human immunoglobulins that bind specifically with human antigens is problematic.

However, when present methods for generating monoclonal antibodies are applied for the purpose of generating human antibodies that have binding specificities for human antigens, obtaining B-lymphocytes which produce human immunoglobulins a serious obstacle, since humans will typically not make immune responses against self-antigens.

Hence, present methods of generating human monoclonal antibodies that are specifically reactive with human antigens are clearly insufficient.

It is evident that the same limitations on generating monoclonal antibodies to authentic self antigens apply where non-human species are used as the source of B-cells for making the hybridoma.

The results of such experiments, however, have been variable, in some cases, producing incomplete or minimal rearrangement of the transgene.

Transgenic animals that cannot switch isotypes are limited to producing heterologous antibodies of a single isotype, and more specifically are limited to producing an isotype that is essential for B cell maturation, such as IgM and possibly IgD, which may be of limited therapeutic utility.

Images